ERBB2 and inflammatory breast carcinoma: In the accompanying research article now published in PLOS Medicine, Charles Swanton and coworkers report the results of an open-label, Phase II trial of afatinib, a tyrosine kinase inhibitor selective for ErbB family receptors, for the treatment of HER2-positive IBC [8].